Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Safestore Holdings (SAFE) by Zaven Boyrazian in The Motley Fool
- Buy Altona Rare Earths (REE) by Hot Stock Rockets in ShareProphets
- Avoid Surgical Innovations Group (SUN) by Steve Moore in ShareProphets
- Outperform OSB Group (OSB) by RBC Capital
- Buy Diageo (DGE) by Harvey Jones in The Motley Fool
- Watch Nexteq (NXQ) by Steve Moore in ShareProphets
- Overweight Jet2 (JET2) by Barclays
- Outperform IntegraFin Holding (IHP) by RBC Capital
- Outperform Volution Group (FAN) by RBC Capital
- Sector Perform Currys (CURY) by RBC Capital
- Buy AstraZeneca (AZN) by Robert Stephens (The Times) in The Times - Tempus
- Avoid Facilities by ADF (ADF) by Steve Moore in ShareProphets
- Buy Tribal Group (TRB) by Hot Stock Rockets in ShareProphets
- Avoid Bunzl (BNZL) by Steve Moore in ShareProphets
- Buy FRP Advisory Group (FRP) by Berenberg
- Buy Beeks Financial Cloud Group (BKS) by Canaccord Genuity
- Buy Harbour Energy (HBR) by Canaccord Genuity
- Avoid The Character Group (CCT) by Steve Moore in ShareProphets
- Buy Rentokil Initial (RTO) by Bank of America
- Neutral Sage Group (SGE) by Goldman Sachs
Oncimmune Holdings (ONC) Share Price
Health Care Sector
NOTE: This is based on 7 open tips for Oncimmune Holdings (ONC)
| Latest Bid : 1.01p | Latest Ask : 1.27p |
| High Today : 1.39p | Low Today : 1.01p |
| This Years High : 29.10p | This Years Low : 1.01p |
| Volume : 399,867 | MKT Cap : £1.27M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Oncimmune Holdings (ONC) Overview
We are leaders in immune biomarkers; our vision is to enable personalised, data-driven clinical decisions across the cancer care continuum. Using our unique expertise and proprietary technology we aim to transform the way disease is diagnosed and treated around the world. We know that detecting the disease early can improve the ability to treat cancer and enhance chances of survival.Oncimmune Holdings (ONC) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Risky Buy | Kirsteen Mackay | Premium Only | 2020-10-13 18:00:00 13/10/2020 | -91.48% |
| Corporate | FinnCap | Premium Only | 2020-03-18 08:55:00 18/03/2020 | – |
| Corporate | FinnCap | Premium Only | 2020-03-04 11:00:00 04/03/2020 | – |
| Corporate | FinnCap | Premium Only | 2020-02-12 09:50:00 12/02/2020 | – |
| Corporate | FinnCap | Premium Only | 2019-11-22 10:25:00 22/11/2019 | – |
Oncimmune Holdings (ONC) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 1.01p | Latest Ask : 1.27p |
| High Today : 1.39p | Low Today : 1.01p |
| This Years High : 29.10p | This Years Low : 1.01p |
| Volume : 399,867 | MKT Cap : £1.27M |
Oncimmune Holdings Overview
We are leaders in immune biomarkers; our vision is to enable personalised, data-driven clinical decisions across the cancer care continuum. Using our unique expertise and proprietary technology we aim to transform the way disease is diagnosed and treated around the world. We know that detecting the disease early can improve the ability to treat cancer and enhance chances of survival.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Oncimmune Holdings Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Risky Buy | Kirsteen Mackay | Premium Only | 2020-10-13 18:00:00 13/10/2020 | -91.48% |
| Corporate | FinnCap | Premium Only | 2020-03-18 08:55:00 18/03/2020 | – |
| Corporate | FinnCap | Premium Only | 2020-03-04 11:00:00 04/03/2020 | – |
| Corporate | FinnCap | Premium Only | 2020-02-12 09:50:00 12/02/2020 | – |
| Corporate | FinnCap | Premium Only | 2019-11-22 10:25:00 22/11/2019 | – |